These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30293699)

  • 1. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors.
    Carrozza F; Santoni M; Piva F; Cheng L; Lopez-Beltran A; Scarpelli M; Montironi R; Battelli N; Tamberi S
    Crit Rev Oncol Hematol; 2018 Nov; 131():1-6. PubMed ID: 30293699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of Emerging Immunotargets of Genitourinary Tumors.
    Montironi R; Santoni M; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Scarpelli M
    Curr Drug Targets; 2016; 17(7):750-6. PubMed ID: 26648079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase-Targeted Cancer Immunotherapy.
    Mizukoshi E; Kaneko S
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor effect against human telomerase reverse transcriptase (hTERT) by vaccination with chemotactic-hTERT gene-modified tumor cell and the combination with anti-4-1BB monoclonal antibodies.
    Lin X; Zhou C; Wang S; Wang D; Ma W; Liang X; Lin C; Wang Z; Li J; Guo S; Zhang Y; Zhang S
    Int J Cancer; 2006 Oct; 119(8):1886-96. PubMed ID: 16708388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uses of telomerase peptides in anti-tumor immune therapy.
    Li H; Katik I; Liu JP
    Methods Mol Biol; 2007; 405():61-86. PubMed ID: 18369818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telomeres and telomerase in T cells of tumor immunity.
    Qian Y; Yang L; Cao S
    Cell Immunol; 2014; 289(1-2):63-9. PubMed ID: 24727158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase in cancer immunotherapy.
    Liu JP; Chen W; Schwarer AP; Li H
    Biochim Biophys Acta; 2010 Jan; 1805(1):35-42. PubMed ID: 19751801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel anticancer therapeutics targeting telomerase.
    Ruden M; Puri N
    Cancer Treat Rev; 2013 Aug; 39(5):444-56. PubMed ID: 22841437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense human telomerase reverse transcriptase could partially reverse malignant phenotypes of gastric carcinoma cell line in vitro.
    Yang SM; Fang DC; Yang JL; Chen L; Luo YH; Liang GP
    Eur J Cancer Prev; 2008 Jun; 17(3):209-17. PubMed ID: 18414191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase based anticancer immunotherapy and vaccines approaches.
    Kailashiya C; Sharma HB; Kailashiya J
    Vaccine; 2017 Oct; 35(43):5768-5775. PubMed ID: 28893481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase-based immunotherapy of cancer.
    Carpenter EL; Vonderheide RH
    Expert Opin Biol Ther; 2006 Oct; 6(10):1031-9. PubMed ID: 16989585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase reverse transcriptase (hTERT) mRNA and telomerase RNA (hTR) as targets for downregulation of telomerase activity.
    Natarajan S; Chen Z; Wancewicz EV; Monia BP; Corey DR
    Oligonucleotides; 2004; 14(4):263-73. PubMed ID: 15665594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
    Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
    Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical localization of hTERT protein in human tissues.
    Yan P; Benhattar J; Seelentag W; Stehle JC; Bosman FT
    Histochem Cell Biol; 2004 May; 121(5):391-7. PubMed ID: 15138842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
    Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
    Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells.
    Napier CE; Veas LA; Kan CY; Taylor LM; Yuan J; Wen VW; James A; O'Brien TA; Lock RB; MacKenzie KL
    Biochim Biophys Acta; 2010 Oct; 1803(10):1142-53. PubMed ID: 20619302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Human telomerase reverse transcriptase as a novel target for tumor immunotherapy].
    Pang JX
    Ai Zheng; 2003 Aug; 22(8):893-5. PubMed ID: 12917043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy advances in uro-genital malignancies.
    Ratta R; Zappasodi R; Raggi D; Grassi P; Verzoni E; Necchi A; Di Nicola M; Salvioni R; de Braud F; Procopio G
    Crit Rev Oncol Hematol; 2016 Sep; 105():52-64. PubMed ID: 27372200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy of tumors with human telomerase reverse transcriptase immortalized human umbilical vein endothelial cells.
    Mu X; Sang Y; Fang C; Shao B; Yang L; Yao K; Zhao X; Gou J; Wei Y; Yi T; Wu Y; Zhao X
    Int J Oncol; 2015 Nov; 47(5):1901-11. PubMed ID: 26398907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.